Biogen Inc 's Revenue in the fiscal year 2025 $ 9,890.60 millions
Biogen Inc 's Revenue in the fiscal year 2024 $ 9,675.90 millions
Biogen Inc 's Revenue in the fiscal year 2023 $ 9,835.60 millions
Biogen Inc 's Revenue in the fiscal year 2022 $ 10,173.40 millions
Biogen Inc 's Revenue in the fiscal year 2021 $ 10,981.70 millions
BIIB Revenue first quarter 2026 Y/Y Growth Comment
Biogen Inc reported Revenue growth of 1.93% year on year in the first quarter 2026, to $ 2,477.80 millions, this is lower than Biogen Inc 's recent average Revenue growth of 9.19%.
Looking into first quarter 2026 results within Biotechnology & Pharmaceuticals industry 41 other companies have achieved higher Revenue growth. While Biogen Inc ' s Revenue increase of 1.93% ranks overall at the positon no. 2597 in the first quarter 2026.
Revenue by Quarter for the Fiscal Years 2023, 2024, 2025, 2026
Biogen Inc 's Q/Q Revenue Growth
Revenue Q/Q Growth Statistics
High
Average
Low
80.67 %
2.78 %
-15.51 %
(March 31, 2004)
BIIB's I. Quarter Q/Q Revenue Comment
Biogen Inc achieved in the I. Quarter 2026 above company average sequential Revenue increase of 8.7%, to $ 2,477.80 millions, from $2,279.40 millions in the fourth quarter. BIIB is undergoing a remarkable growth, with claiming higher then normal increase, and additionally increasing rate.
Within Biotechnology & Pharmaceuticals industry 18 other companies have achieved higher Revenue quarter on quarter growth. While Biogen Inc 's Revenue growth quarter on quarter, overall rank is 887.
Biogen Inc achieved in the I. Quarter 2026 above company average sequential Revenue increase of 8.7%, to $ 2,477.80 millions, from $2,279.40 millions in the fourth quarter. BIIB is undergoing a remarkable growth, with claiming higher then normal increase, and additionally increasing rate.
Within Biotechnology & Pharmaceuticals industry 18 other companies have achieved higher Revenue quarter on quarter growth. While Biogen Inc 's Revenue growth quarter on quarter, overall rank is 887.
Biogen Inc 's 12 Months Revenue Growth Year on Year
Revenue TTM Growth
12 Months Ending (Mar 31 2026)
12 Months Ending (Dec 31 2025)
12 Months Ending (Sep 30 2025)
12 Months Ending (Jun 30 2025)
12 Months Ending (Mar 31 2025)
Cumulative Revenue 12 Months Ending
$ 9,937.40
$ 9,890.60
$ 10,065.90
$ 9,997.00
$ 9,816.40
Y / Y Revenue Growth (TTM)
1.23 %
2.22 %
4.77 %
3.36 %
1.59 %
Year on Year Revenue Growth Overall
Ranking
# 2471
# 356
# 2506
# 2318
# 984
Seqeuential Revenue Change (TTM)
0.47 %
-1.74 %
0.69 %
1.84 %
1.45 %
Seq. Revenue Growth (TTM) Overall
Ranking
# 2486
# 1469
# 2260
# 2078
# 1945
Cumulative Revenue growth Comment
With the quarterly Revenue reported in the Mar 31 2026 period, Biogen Inc 's cumulative twelve months Revenue were $ 9,937 millions, company would post below average annual Revenue growth of 1.45% year on year, if the fiscal year would end at Mar 31 2026. A slow-down in the Biogen Inc 's Revenue growth from the 2279.4% growth in Dec 31 2025.
In the Healthcare sector 355 other companies have achieved higher trailing twelve month Revenue growth. While Revenue growth total ranking has deteriorated compare to previous quarter from 356 to 2471.
With the quarterly Revenue reported in the Mar 31 2026 period, Biogen Inc 's cumulative twelve months Revenue were $ 9,937 millions, company would post below average annual Revenue growth of -22.17% year on year, if the fiscal year would end at Mar 31 2026. A slow-down in the Biogen Inc 's Revenue growth from the 2279.4% growth in Dec 31 2025.
In the Healthcare sector 355 other companies have achieved higher trailing twelve month Revenue growth. While Revenue growth total ranking has deteriorated compare to previous quarter from 356 to 2471.
About Biogen Inc Revenue Growth Rates (BIIB), Current and Historic Growth - CSIMarket Analysis
How we calculate this
This page is based on issuer-reported fundamentals and CSIMarket’s U.S. equities database (20+ years).
Growth is computed using year-over-year (Y/Y), sequential, and trailing-twelve-month (TTM) methods.
Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com
Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.
3.35%